

Byooviz costs about $1,130 per injection. Learn how to save with Biogen's copay program, patient assistance, and other strategies in 2026.
Byooviz (Ranibizumab-nuna) was designed to be a more affordable alternative to Lucentis for treating serious retinal conditions. And at a list price of about $1,130 per vial, it's roughly 40% cheaper than Lucentis, which costs approximately $1,850 per injection.
But let's be real — $1,130 per injection, given once a month, adds up fast. That's potentially $13,560 per year before insurance. Even with coverage, copays and coinsurance for specialty biologics can be hundreds of dollars per injection.
The good news: there are real programs and strategies that can significantly reduce — or even eliminate — what you pay for Byooviz. Here's everything you need to know.
If you don't have insurance or your plan doesn't cover Byooviz, here's what you're looking at:
For comparison, here's what other anti-VEGF injections cost:
Byooviz is clearly cheaper than Lucentis, Eylea, and Vabysmo, but it's still a specialty biologic with a significant price tag. If you're paying cash, you'll want to explore every savings option available.
The primary savings program for Byooviz is the Biogen Copay Program. If you have commercial insurance (not Medicare, Medicaid, or other government insurance), you may qualify to have your out-of-pocket costs reduced to as low as $0 per injection.
There are actually two separate programs:
Covers your out-of-pocket cost for the Byooviz medication itself. This applies to the drug copay or coinsurance your insurance charges for the injection.
Covers your out-of-pocket cost for the injection procedure — the office visit and administration fee your doctor charges. Each program has its own eligibility requirements and annual caps on assistance.
This is the single most valuable savings tool for commercially insured patients. If you have commercial insurance and you're paying more than $0 for Byooviz, call Biogen today.
If you don't have insurance or are underinsured, the Biogen Copay Program won't apply to you. But there are other options:
Biogen offers assistance for eligible patients who can't afford their medications. Qualifying criteria typically include income limits and lack of adequate insurance coverage. Contact Biogen Biosimilar Support Services at 1-877-422-8360 to learn about eligibility and apply.
NeedyMeds.org maintains a database of patient assistance programs, discount drug cards, and other resources for people who can't afford their medications. Search for Ranibizumab or Byooviz to find applicable programs.
RxAssist.org is another comprehensive resource for finding patient assistance programs. It includes programs from pharmaceutical manufacturers, government agencies, and nonprofit organizations.
Some states offer their own prescription assistance programs that may help cover the cost of specialty medications like Byooviz. Check with your state's department of health or insurance commission to see what's available in your area.
If you're on Medicare, you can't use manufacturer copay cards (that's a federal rule). But you still have options:
If cost is your primary concern, talk to your doctor about Avastin (Bevacizumab). At approximately $50-$75 per compounded dose, it's a fraction of the cost of Byooviz. While Avastin is not FDA-approved for eye conditions, large clinical trials have shown it produces comparable results for wet AMD. Many insurers actually require patients to try Avastin first before approving more expensive anti-VEGF treatments.
Read more about this and other options in our article on alternatives to Byooviz.
For some conditions, your doctor may be able to extend the interval between Byooviz injections after an initial series of monthly treatments. For wet AMD, some patients may be treated with monthly injections for three months and then transition to less frequent dosing based on how their eyes respond. Fewer injections means lower annual costs.
This is a clinical decision — always follow your doctor's recommended schedule. But it's worth asking whether an extended dosing regimen is appropriate for your situation.
Because Byooviz is administered through the buy-and-bill model, the total cost you pay (drug + administration) can vary between providers. If you're paying out of pocket or have high coinsurance, call multiple retinal specialists to compare what they charge. Hospital outpatient departments often charge more than independent physician offices for the same injection.
If you can't find Byooviz at your current provider, use Medfinder to search for availability near you. Having more options means you can also compare costs and choose a provider that works for your budget.
Byooviz is already one of the more affordable anti-VEGF options for treating wet AMD, retinal vein occlusion, and myopic choroidal neovascularization. But "affordable" is relative when you're talking about a specialty biologic that costs over $1,000 per injection.
The most important takeaway: don't skip your injections because of cost. There are real savings programs available — Biogen's copay program alone can bring your costs to $0 if you have commercial insurance. For Medicare and uninsured patients, patient assistance programs and alternative medications like Avastin provide lower-cost pathways to treatment.
Talk to your doctor, call Biogen at 1-877-422-8360, and explore resources like NeedyMeds and RxAssist. Your vision is worth protecting, and the help is out there.
For more information, read our complete guide to Byooviz or learn how to find Byooviz in stock near you.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.